“BeneFITs” to Increase Colorectal Cancer Screening in Priority Populations
Authors: Beverly B. Green, Gloria D. Coronado
Journal: JAMA Internal Medicine (2014)

Colorectal cancer (CRC) is a leading cause of cancer death in the United States. Many CRC deaths could be averted by screening because screening decreases both CRC incidence and mortality by 30% to 60%.1 Although CRC screening rates have risen in recent years, with 65% of Americans aged 50 to 75 years reporting being up-to-date,2 rates remain suboptimal and are marked by pronounced racial/ethnic and socioeconomic disparities. Only 53% of Latinos2 and 39% of individuals with incomes below the federal poverty level are current for CRC screening (Figure). Low socioeconomic status is also associated with higher rates of CRC mortality.3 Increasing screening in priority populations could substantially decrease morbidity and mortality from CRC.



Figure

Percentage of Adults Aged 50 to 75 Years Who Received Colorectal Cancer Screening by Family Income Level—National Health Interview Survey, United States, 2010



These disparities may be attributable in part to the fact that some professional societies and often physicians recommend colonoscopy as the best CRC screening method. However, increasing evidence shows that patients who are offered only colonoscopy for initial screening might not screen at all. Inadomi et al4 found that patients offered fecal occult blood testing (FOBT) or choice of FOBT and colonos-copy were twice as likely to screen as those offered only colonoscopy—in particular, Latinos and Asian individuals were significantly more likely to choose FOBT.4 Gupta and colleagues,5 in a recent article in the Journal of the National Cancer Institute, provide a framework for decreasing CRC disparities based on the message that “the best test is the one that gets done.”

A drawback to FOBT screening is that it must be done annually to meet the evidence-based recommendations of the US Preventive Services Task Force (USPSTF). In contrast, recommended colonoscopy screening for average-risk individuals is only once every 10 years. Although adherence to annual FOBT screening is high in efficacy trials, we have lacked information on repeat screening in community settings.

In this issue of JAMA Internal Medicine, Baker et al6 provide evidence that a mailed FOBT program can achieve repeat screening rates of over 82% in a largely low-income Spanish-speaking population. The study used fecal immunochemical testing (FIT), a type of FOBT that is more user friendly. FIT has no dietary restrictions, requires only 1 sample, and can be performed in the privacy of one’s home, leading to higher adherence rates.7 lectronic health records can be leveraged to efficiently deliver FOBT mailings annually without clinic visits. In an integrated health care organization setting,a randomized trial by Green et al8 found that people offered an automated mailed FOBT program with an option to choose colonoscopy instead were twice as likely to be up-to-date for CRC screening over 2 study years compared with usual care, mainly because participants completed FOBT in both years. The mailed FOBT program was also less expensive than usual care because the program slightly reduced expensive screening colonoscopies.

A disappointing result in the study by Baker et al6 was that only 60% of individuals with a positive screening FOBT result completed follow-up diagnostic colonoscopy, even though it was offered at no cost and a health professional navigator provided support with scheduling, preparation, and transportation. Follow-up colonoscopy is crucial, since the chance of CRC is as high as 4% in individuals with a positive FOBT result, and almost one-third have advanced precancerous adenomas. Lack of follow-up colonoscopy defeats the purpose of a FOBT screening program. Other studies using navigators have had higher follow-up rates,9 and a program that included a registry and physician reminders led to colonoscopy completion rates of over 80%.10

Baker et al6 do not describe the reasons for low rates of follow-up diagnostic colonoscopy, but for many people in the United States, the barriers to this procedure are substantial and include limited availability and cost. The Patient Protection and Affordable Care Act of 2010 (ACA) mandates that screening tests recommended by the USPSTF, including CRC testing, be covered in full with no patient out-of-pocket expenses. However, this mandate does not include follow-up diagnostic colo-noscopy, for which insurance copays and deductibles apply. Individuals choosing FOBT might be unpleasantly surprised to learn that, depending on their health plan, colonoscopy after a positive FOBT result could cost from $200 to $3000. In an example of the potentially dangerous effects of this policy, a physician colleague described a patient with a positive FOBT result who could not afford follow-up colonoscopy because of her $10 000 health plan deductible. The patient and physician were left worrying about her possible CRC, and the physician had doubts about recommending FOBT to other patients. Decreasing CRC disparities will require an ACA policy change to cover CRC screening by FOBT as a 2-part test, with diagnostic colonoscopy after a positive FOBT result as the second part.

In fact, in most states, Medicaid already covers both initial CRC screening (both colonoscopy and FOBT) and follow-up colonoscopy testing with no patient out-of-pocket costs. Therefore, Medicaid expansion under the ACA, which covers adults at 138% of the federal poverty level, offers a partial solution for reducing CRC screening disparities. In April 2014, the Center for Medicare & Medicaid Services reported that more than 3 million additional people had enrolled in Medicaid—most adults and many age-eligible for CRC screening. However, not all states are participating in Medicaid expansion, and in participating states, low-income, racial/ethnic minority individuals might not qualify because of their undocumented status. In addition, some gastroenterologists will not accept Medicaid patients because colonoscopy reimbursement rates are lower than Medicare and commercial insurance rates.

The Medicaid policy offers the right “beneFITs” by covering both FOBT testing by FIT and follow-up colonoscopy. Baker et al6 provide evidence that mailed FITs achieve high rates of repetitive screening in populations who currently have the lowest rates. Population-based mailed FIT programs that are aligned with benefits have the potential to rapidly reduce CRC disparities.